Fig. 5: Neuroprotective effect of Oprm1 on RGC survival.

a Experimental timeline of AAV2 infection, injury induction, and tissue collection in the ONC model. b Neuroprotective effect of Oprm1 overexpression on RGC survival in the ONC model. Pan-RGC marker vGlut2-Sun1GFP reflected RGC numbers under different conditions. DPI, days post-injury. c and d Quantification of RGC survival rate in ONC model at 5 or 14 days post-ONC. n = 4 or 5 mice for independent experimental conditions. e Experimental timeline of AAV2 infection, NMDA toxicity induction and tissue collection in the NMDA toxicity model. f Neuroprotective effect of Oprm1 overexpression on RGC survival under NMDA toxicity. g Quantification of RGC survival rate seven days in NMDA toxicity model. n = 5 mice for independent experimental conditions. h Experimental timeline of morphine treatment, crush injury induction, and tissue collection. i Neuroprotective effect of morphine treatment on RGC survival at five days post-ONC. j Quantification of RGC survival rate. n = 4 or 5 mice for independent experimental conditions. k Experimental timeline of NMDA toxicity induction, naloxone treatment, and tissue collection. l The effect of Oprm1 antagonist Naloxone on ipRGC survival rate in the NMDA toxicity model. Fluorescent micrographs of ipRGC marker OPN4 and pan-RGC marker vGlut2-Sun1GFP reveal the levels of ipRGC survival. The red channel represents OPN4 staining, and the green channel represents the nucleus membrane GFP in RGCs. White circles with dash lines mark the ipRGCs. m Quantification of ipRGC survival rate under naloxone treatment in the NMDA model. n = 4 or 5 mice for each independent experimental condition. Panels c, d, g, j, and m data are presented as mean values ± SEM: unpaired t-test, two-tailed. The scale bar is 50 μm, which applies to all micrographs in the figure. Source data are provided as a Source Data file.